Engineering the Future of Synthetic DNA

Engineering_the_Future
In the past decade, the synthetic biology market has seen fledgling companies rise to IPO smashing power players, as the demand for high-quality, engineered biomolecules grows exponentially. The synthesis of DNA molecules and libraries has always been at the vanguard of synthetic biology endeavors but has seen its share of challenges that scientists have to navigate. Technological advancements and democratization of synthesis modalities have expanded access to an even wider range of life science investigators—presenting new challenges, but also a host of opportunities for new solutions.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Optimize This! Enhancing the Quality and Consistency of Cannabis and Extraction

Technology Networks

Everyone makes the best extracts. But are they optimized? And what does “the best” mean; does it mean high yield, high quality, or both? And what is quality anyway? Quality begins in the cultivation process and continues throughout the handling of the product from seed to sale. At OutCo, we’ve studied our production pipeline and extraction methodologies to offer optimized products to our patients. Finding the ideal balance between yield and consumer rating, we were able to optimize extraction protocols for controlled mixtures of compounds. Our custom methods enable us to create products with designer cannabinoid and terpene ratios, customized to patients’ and doctors’ needs. All of this was achieved in an efficient manner through the use of design of experiment (DoE) techniques, and continuous improvement of all processes.
Watch Now

Cell and Gene Therapies

More than US$55 billion has been invested in developing gene modification and cell therapy platforms over the past three years. While the science has advanced, the practical components of launch and optimizing
Watch Now

Exploring the genetic landscape of solid tumors using whole-genome copy number analysis

Labroots

Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, recent publications have shown that in certain types of cancers, copy number variations (CNVs) play a more important role than somatic mutations.
Watch Now

Gene Therapy Downstream Manufacturing

Gene therapies provide innovative options for treating patients, particularly where other traditional therapeutics have been ineffective. The industry continues to grow and mature from research to approved therapeutics.
Watch Now

Spotlight

resources